Kidney Failure Clinical Trial
— GRAFTOfficial title:
Effect of Dipyridamole Plus Aspirin on Hemodialysis Graft Patency
The objective of the study is to determine whether Aggrenox (Boehringer-Ingelheim) prolongs primary unassisted patency in newly created arteriovenous grafts. This record previously included information for both the GRAFT and FISTULA trials.
Status | Completed |
Enrollment | 649 |
Est. completion date | January 31, 2008 |
Est. primary completion date | January 31, 2008 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion criteria: - Age 18-21 depending on state regulations - Life expectancy of at least six months - Chronic renal failure with anticipated start of hemodialysis within six months of enrollment, or current dialysis dependence - A new or planned arteriovenous (AV) graft placed in any location for the purpose of hemodialysis. (Any type of graft material and any configuration of the access is acceptable). - The patient is expected to stay at a participating dialysis facility for at least 6 months. - The patient's physician(s) will allow the patient to participate. - Ability to give informed consent. Exclusion Criteria: - Women must not be pregnant, breastfeeding, or plan to be pregnant during the course of the study. - The presence of ongoing bleeding. - The presence of a known bleeding disorder (e.g., hemophilia or von Willebrand's disease). - Recent bleeding episode requiring transfusion within 12 weeks of entry. - The presence of acute ulcer disease. Acute ulcer disease is defined as a new diagnosis of peptic disease including esophagitis, gastritis, or ulcer or the initiation of treatment with proton pump inhibitors, H2 blockers or therapy for Helicobacter pylori within three months prior to obtaining consent. - Known allergy or adverse reaction to Aggrenox or any of its study components (dipyridamole and aspirin). - Required use of warfarin, dipyridamole, non-steroidal antiinflammatory drugs or other antiplatelet agents other than aspirin. - Current uncontrolled hypertension with systolic blood pressure in excess of 200 mm Hg or diastolic blood pressure in excess of 115 mm Hg. - Baseline platelet count less than 75,000/mm3. - Known advanced liver disease with decompensated cirrhosis, jaundice, ascites or bleeding varices. - Current problem with substance abuse. - Concurrent participation in another medical intervention trial. - Anticipated non-compliance with medical care based on physician judgment. - Patient refusal. |
Country | Name | City | State |
---|---|---|---|
United States | University of Alabama at Birmingham | Birmingham | Alabama |
United States | Boston University Medical Center | Boston | Massachusetts |
United States | University of Texas Southwestern | Dallas | Texas |
United States | Duke University Medical Center | Durham | North Carolina |
United States | University of Iowa | Iowa City | Iowa |
United States | Vanderbilt University | Nashville | Tennessee |
United States | Maine Medical Center | Portland | Maine |
United States | Washington University | Saint Louis | Missouri |
United States | Wake Forest University | Winston-Salem | North Carolina |
Lead Sponsor | Collaborator |
---|---|
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Baystate Medical Center, Boston University, CAMC Health System, Duke University, Emory University, Maine Medical Center, St. Louis University, The Cleveland Clinic, Tyler Nephrology Associates, University of Alabama at Birmingham, University of Iowa, University of Texas Southwestern Medical Center, Vanderbilt University, Vascular Surgery Associates LLC, Washington University School of Medicine |
United States,
Dixon BS, Beck GJ, Dember LM, Depner TA, Gassman JJ, Greene T, Himmelfarb J, Hunsicker LG, Kaufman JS, Lawson JH, Meyers CM, Middleton JP, Radeva M, Schwab SJ, Whiting JF, Feldman HI; DAC Study Group. Design of the Dialysis Access Consortium (DAC) Aggrenox Prevention Of Access Stenosis Trial. Clin Trials. 2005;2(5):400-12. — View Citation
Dixon BS, Beck GJ, Vazquez MA, Greenberg A, Delmez JA, Allon M, Dember LM, Himmelfarb J, Gassman JJ, Greene T, Radeva MK, Davidson IJ, Ikizler TA, Braden GL, Fenves AZ, Kaufman JS, Cotton JR Jr, Martin KJ, McNeil JW, Rahman A, Lawson JH, Whiting JF, Hu B, — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04510090 -
Evaluate the Safety, Tolerability, and PK of EP547 in Healthy Subjects and Subjects With Cholestatic or Uremic Pruritus
|
Phase 1 | |
Completed |
NCT02546037 -
Clotting With Different Dialyzer Membranes
|
||
Recruiting |
NCT02545920 -
To Assess Ear Blood Flow During Dialysis
|
||
Completed |
NCT02134314 -
C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI
|
Phase 1/Phase 2 | |
Recruiting |
NCT01912001 -
Virtual Ward for Home Dialysis
|
N/A | |
Completed |
NCT00986947 -
Desensitization of Highly Sensitized Deceased Donor Renal Transplantation Candidates
|
Phase 2 | |
Completed |
NCT01158742 -
Live Kidney Donor Study -Renal Function Study
|
N/A | |
Withdrawn |
NCT00807274 -
Renal Function in Adults With Congenital Heart Disease.
|
N/A | |
Completed |
NCT00765661 -
Pharmacokinetics of LCP-Tacro(TM) Once Daily And Prograf® Twice A Day in Adult De Novo Kidney Transplant Patients
|
Phase 2 | |
Completed |
NCT00369382 -
Study Of The Safety And Efficacy Of Conversion From A CNI To Sirolimus In Renally-Impaired Heart Transplant Recipients
|
Phase 4 | |
Completed |
NCT00183248 -
Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients
|
Phase 1/Phase 2 | |
Enrolling by invitation |
NCT05324878 -
Honoring Individual Goals and Hopes: Implementing Advance Care Planning for Persons With Kidney Disease on Dialysis
|
||
Completed |
NCT05272800 -
BIS-guided Fluid Management in HD Patients
|
N/A | |
Completed |
NCT03836508 -
Effect of Dialysis Membranes on Inflammatory and Immune Processes in Hemodialysis
|
N/A | |
Completed |
NCT01756508 -
Eculizumab for Prevention and Treatment of Kidney Graft Reperfusion Injury
|
Phase 2 | |
Completed |
NCT03723668 -
Kidney Transplant Outcome and Organ Acceptance Practice Pattern: A Nationwide Analyses in the US and France
|
||
Recruiting |
NCT04277377 -
Nanoparticle for DSA Removal
|
||
Terminated |
NCT00450333 -
Dynepo Infrequent Dosing Study
|
Phase 3 | |
Terminated |
NCT03840343 -
Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease
|
Phase 1 | |
Recruiting |
NCT04714853 -
Different Dialysis Modalities and Diet on Gastrointestinal Biome and Azotaemic Toxins
|